stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Operating cash flow
HUTCHMED (China) Limited Sponsored ADR's operating cash flow for fiscal 2025 was −$64.7M, compared with $497.0K in fiscal 2024. Over the twelve months to 30 June 2026 it was −$124.8M. Over the past ten years it has ranged from −$268.6M (fiscal 2022) to $219.3M (fiscal 2023); the current reading is higher than 36% of that period. HUTCHMED (China) Limited Sponsored ADR ranks 82nd of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$64.7M | — |
| FY2024 | $497.0K | (99.77%) |
| FY2023 | $219.3M | — |
| FY2022 | −$268.6M | — |
| FY2021 | −$204.2M | — |
| FY2020 | −$62.1M | — |
| FY2019 | −$80.9M | — |
| FY2018 | −$32.8M | — |
| FY2017 | −$8.9M | — |
| FY2016 | −$9.6M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $12.2M | — |
| Dec 2025 | −$64.7M | — |
| Jun 2025 | −$72.9M | — |
| Dec 2024 | $497.0K | — |
| 11 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | $367.5M |
| TRLV Trulieve Cannabis Corp. compare | $242.5M |
| PRGO Perrigo Company plc compare | $240.6M |
| PBH Prestige Consumer Healthcare Inc. compare | $229.8M |
| ANIP ANI Pharmaceuticals, Inc. compare | $229.2M |
| XERS Xeris Biopharma Holdings, Inc. compare | $73.6M |
| ALVO Alvotech compare | −$11.8M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR | −$124.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement